The University of Texas MD Anderson Cancer Center
Dr. Bulent Ozpolat is an associate professor in Department of Experimental Therapeutics, Division of Cancer Medicine, UTMDACC, Houston, TX. Dr. Ozpolat is a member of Center for Targeted Therapy, Alliance for Nano heath, Texas Center Cancer Nanomedicine (CCNE), Ovarian Cancer Moonshots, Non-Coding RNA Center at MDACC and closely collaborating Dr. Kevin Dalby (UT-Austin) Dr. Michael Ittmann, (Baylor College of Medicine), Dr. James Sahn (UT-Austin), Jonathan Sessler (UT-Austin) Dr. Fahri Saatcioglu (University of Oslo). As part of ovarian cancer study group Dr. Ozpolat is collaborating with Drs. Lopez-Berestein, Sood and Coleman to develop tumor- targeted therapies. He serves as a reviewer for several journals and study sections and published many papers and review articles in high impact journals and contributed to 12 book chapters. Dr. Ozpolat is holding a patent and several applications are pending.
Developing highly specific tumor-targeting nanocarriers (nanoliposomes and polymer-based nanoparticles) for the delivery of oligonucleotides, non-coding RNAs (i.e., siRNA, microRNA , anti-Mirs), peptides, proteins, drugs and small molecule inhibitors, Studying the role of survival pathways, including autophagy and eEF2-kinase (eEF2K) signaling and development of novel therapeutic agents (small molecule inhibitors and siRNA-based nanotherapeutics) that target these pathways and Development of these agents into clinical strategies for patients.